

Mario Petrini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2882389/publications.pdf>

Version: 2024-02-01

86
papers

1,070
citations

471509

17
h-index

477307

29
g-index

87
all docs

87
docs citations

87
times ranked

2225
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. <i>Blood</i> , 2016, 128, 497-503.	1.4	144
2	NM23 gene expression correlates with cell growth rate and S-phase. <i>International Journal of Cancer</i> , 1995, 60, 837-842.	5.1	66
3	Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment. <i>Stem Cells Translational Medicine</i> , 2018, 7, 305-314.	3.3	65
4	ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 1419-1432.	3.3	46
5	Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2016, 101, e66-e68.	3.5	36
6	High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naïve lymphocytes and prevents TTV reactivation. <i>Leukemia Research</i> , 2018, 70, 20-24.	0.8	36
7	Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2. <i>Frontiers in Oncology</i> , 2020, 10, 1428.	2.8	36
8	The CoV-2 outbreak: how hematologists could help to fight Covid-19. <i>Pharmacological Research</i> , 2020, 157, 104866.	7.1	36
9	Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2015, 16, 22811-22829.	4.1	33
10	LH and FSH promote migration and invasion properties of a breast cancer cell line through regulatory actions on the actin cytoskeleton. <i>Molecular and Cellular Endocrinology</i> , 2016, 437, 22-34.	3.2	31
11	Lithium in the treatment of neutropenia. <i>Current Opinion in Hematology</i> , 2012, 19, 52-57.	2.5	30
12	The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice. <i>Frontiers in Oncology</i> , 2019, 9, 528.	2.8	27
13	Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients. <i>Oncotarget</i> , 2016, 7, 72311-72321.	1.8	26
14	Plasticity of human dental pulp stromal cells with bioengineering platforms: A versatile tool for regenerative medicine. <i>Micron</i> , 2014, 67, 155-168.	2.2	23
15	Polycomb genes are associated with response to imatinib in chronic myeloid leukemia. <i>Epigenomics</i> , 2015, 7, 757-765.	2.1	22
16	A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. <i>Hematological Oncology</i> , 2021, 39, 41-50.	1.7	22
17	Digital Droplet PCR is a Specific and Sensitive Tool for Detecting IDH2 Mutations in Acute Myeloid Leukemia Patients. <i>Cancers</i> , 2020, 12, 1738.	3.7	20
18	The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2018, 8, 555.	2.8	18

#	ARTICLE	IF	CITATIONS
19	Piezoelectric Signals in Vascularized Bone Regeneration. <i>Biomolecules</i> , 2021, 11, 1731.	4.0	18
20	Allogeneic hematopoietic stem cell transplant recipients and parasitic diseases: A review of the literature of clinical cases and perspectives to screen and follow-up active and latent chronic infections. <i>Transplant Infectious Disease</i> , 2017, 19, e12669.	1.7	16
21	A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMENSE consortium and meta-analysis. <i>Oncotarget</i> , 2016, 7, 59029-59048.	1.8	16
22	Mesangiogenic Progenitor Cells Derived from One Novel CD64 ^{bright} CD31 ^{bright} CD14 ^{neg} Population in Human Adult Bone Marrow. <i>Stem Cells and Development</i> , 2016, 25, 661-673.	2.1	14
23	Pore Size Distribution and Blend Composition Affect In Vitro Prevascularized Bone Matrix Formation on Poly(Vinyl Alcohol)/Gelatin Sponges. <i>Macromolecular Materials and Engineering</i> , 2017, 302, 1700300.	3.6	14
24	The WNT Pathway Is Relevant for the BCR-ABL1-Independent Resistance in Chronic Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 532.	2.8	14
25	The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. <i>Oncotarget</i> , 2017, 8, 88021-88033.	1.8	14
26	Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma. <i>Blood</i> , 2022, 140, 1378-1389.	1.4	14
27	Pooled human serum: A new culture supplement for bioreactor-based cell therapies. Preliminary results. <i>Cytotherapy</i> , 2018, 20, 556-563.	0.7	13
28	Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial. <i>Blood Advances</i> , 2022, , .	5.2	13
29	Association of the <i>hOCT1/ABCB1</i> genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 767-773.	2.3	12
30	How to treat splenic marginal zone lymphoma (SMZL) in patients unfit for surgery or more aggressive therapies: experience in 30 cases. <i>Journal of Chemotherapy</i> , 2017, 29, 126-129.	1.5	12
31	Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients. <i>British Journal of Haematology</i> , 2018, 183, 375-384.	2.5	11
32	VDTPACEAs Salvage Therapy For Heavily Pretreated MM Patients. <i>Blood</i> , 2013, 122, 5377-5377.	1.4	11
33	Lenograstim and filgrastim effects on neutrophil motility in patients undergoing chemotherapy: Evaluation by computer-assisted image analysis. <i>American Journal of Hematology</i> , 2001, 66, 306-307.	4.1	10
34	Isolating Mesangiogenic Progenitor Cells (MPCs) from Human Bone Marrow. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	10
35	Tympanic Membrane Collagen Expression by Dynamically Cultured Human Mesenchymal Stromal Cell/Star-Branched Poly(μ -Caprolactone) Nonwoven Constructs. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 3043.	2.5	10
36	Activation of the zinc-sensing receptor GPR39 promotes T-cell reconstitution after hematopoietic cell transplant in mice. <i>Blood</i> , 2022, 139, 3655-3666.	1.4	10

#	ARTICLE	IF	CITATIONS
37	High NESTIN Expression Marks the Endosteal Capillary Network in Human Bone Marrow. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 596452.	3.7	9
38	Low-Frequency Electromagnetic Fields Do Not Affect Cell Growth, Erythroid Differentiation, and Virus Production in Variant Lines of Untreated and Dimethyl Sulfoxide-Treated Friend Erythroleukemia Cells. <i>Electromagnetic Biology and Medicine</i> , 1993, 12, 135-146.	0.4	8
39	Identification of miRSNPs associated with the risk of multiple myeloma. <i>International Journal of Cancer</i> , 2017, 140, 526-534.	5.1	8
40	Interference of Monoclonal Gammopathy with Fibrinogen Assay Producing Spurious Dysfibrinogenemia. <i>TH Open</i> , 2019, 03, e64-e66.	1.4	8
41	Myeloid neoplasms and autoimmune diseases: markers of association. <i>Clinical and Experimental Rheumatology</i> , 2022, 40, 49-55.	0.8	8
42	Early Diagnosis of Neutropenic Enterocolitis by Bedside Ultrasound in Hematological Malignancies: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4277.	2.4	6
43	Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status?. <i>Blood</i> , 2013, 122, 1482-1482.	1.4	6
44	Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients. <i>European Journal of Haematology</i> , 2020, 104, 138-144.	2.2	5
45	A polygenic risk score for multiple myeloma risk prediction. <i>European Journal of Human Genetics</i> , 2022, 30, 474-479.	2.8	5
46	Mesenchymal Stromal Cell Culture and Delivery in Autologous Conditions: A Smart Approach for Orthopedic Applications. <i>Journal of Visualized Experiments</i> , 2016, , .	0.3	4
47	A rare case of de novo CD5+ diffuse large B-cell lymphoma in leukemic phase and positive for CD13. <i>Hematology Reports</i> , 2017, 9, 7437.	0.8	4
48	Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation. <i>Frontiers in Medicine</i> , 2021, 8, 712070.	2.6	4
49	Myeloid neoplasms and autoimmune diseases: markers of association. <i>Clinical and Experimental Rheumatology</i> , 2021, , .	0.8	4
50	Sorafenib As Monotherapy or in Association With Cytarabine and Clofarabine for the Treatment of Relapsed/Refractory FLT3 ITD-Positive Advanced Acute Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, e13-e17.	0.4	3
51	Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib. <i>Hematological Oncology</i> , 2015, 33, 250-252.	1.7	3
52	Morphologic and immunophenotypic features of a case of acute monoblastic leukemia with unusual positivity for Glycophorin-A. <i>Hematology Reports</i> , 2018, 10, 7823.	0.8	3
53	The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients. <i>Cancer Cell International</i> , 2019, 19, 83.	4.1	3
54	Different types of amyloid concomitantly present in the same patients. <i>Hematology Reports</i> , 2019, 11, 7996.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Poly(vinyl alcohol)/Gelatin Scaffolds Allow Regeneration of Nasal Tissues. <i>Applied Sciences</i> (Switzerland), 2021, 11, 3651.	2.5	3
56	Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter Folldela Study. <i>Cancers</i> , 2022, 14, 654.	3.7	3
57	Effects of Repeated Exposure to High-Voltage Electric Discharges and Low-Frequency Electromagnetic Fields on Cultured Mouse P3A–63Ag8 Plasmocytoma Cells. <i>Electromagnetic Biology and Medicine</i> , 1993, 12, 125-134.	0.4	2
58	PRDI-BF1 and PRDI-BF1 ^{Δ2} isoform expressions correlate with disease status in multiple myeloma patients. <i>Hematology Reports</i> , 2017, 9, 7201.	0.8	2
59	Long-term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high-dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2021, 192, 1011-1014.	2.5	2
60	Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study. <i>Medicina</i> (Lithuania), 2021, 57, 900.	2.0	2
61	Phase II Study of the Combination of Interleukin-2 with Zoledronic Acid As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 5697-5697.	1.4	2
62	Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma. <i>Oncotarget</i> , 2019, 10, 6781-6790.	1.8	2
63	Large granular lymphocytes (LGL) in primary Sjögren syndrome (pSS): immunophenotype and review on the pathological role of T cells in pSS. <i>Blood Research</i> , 2020, 55, 120-123.	1.3	2
64	Leptomeningeal myelomatosis diagnosed by an eight-color single tube in dried formulation. A case report. <i>Cytometry Part B - Clinical Cytometry</i> , 2018, 94, 721-723.	1.5	1
65	Uncommon Presentation of a Common Leukemia (Chronic Lymphocytic Leukemia): Case Report. <i>SN Comprehensive Clinical Medicine</i> , 2020, 2, 651-652.	0.6	1
66	Role of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkin's Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen. <i>Blood</i> , 2007, 110, 4498-4498.	1.4	1
67	Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation. <i>Clinical Hematology International</i> , 2020, 2, 129.	1.7	1
68	Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study. <i>Advances in Hematology</i> , 2022, 2022, 1-10.	1.0	1
69	Grafting of Expanded Mesenchymal Stem Cells without Associated Procedure in a Healed Case of Ulna Pseudarthrosis: A Case Report. <i>Surgical Technology International</i> , 2016, 28, 289-92.	0.2	1
70	Joint Pain and Arthritis as First Clinical Manifestation of Systemic Amyloidosis and Multiple Myeloma: Case Report and Brief Literature Review. <i>Hematology Reports</i> , 2022, 14, 19-23.	0.8	1
71	The Onset of Monoclonal and Oligoclonal Gammopathies Is a Good Prognostic Factor after Allogeneic Stem Cell Transplantation. <i>Acta Haematologica</i> , 2019, 141, 7-11.	1.4	0
72	Hematogones in patients with acute myeloid leukaemia: Prognostic value and correlation with minimal residual disease. <i>Leukemia Research Reports</i> , 2021, 15, 100234.	0.4	0

#	ARTICLE	IF	CITATIONS
73	Comparison of Bone Marrow Biopsy, Flow Cytometry and PCR Assays To Detect Bone Marrow Involvement in B-Cell Non-Hodgkin Lymphomas.. Blood, 2005, 106, 4670-4670.	1.4	0
74	Pharmacogenetic Study on Multiple Myeloma Patients Treated with DAV Regimen and Autologous Stem Cell Transplantation.. Blood, 2007, 110, 3468-3468.	1.4	0
75	Age-Dependent Influence of TNF- α Polymorphism on Progression Free Survival of ASCT In Multiple Myeloma Patients. Blood, 2010, 116, 1829-1829.	1.4	0
76	Safety and Efficacy of Pegylated Liposomal Doxorubicin In Combination with Dexamethasone and Bortezomib (VMD) or Lenalidomide (RMD) In Multiple Myeloma Refractory/Relapsed Patients. Blood, 2010, 116, 5033-5033.	1.4	0
77	Polymorphisms in Regulators of Xenobiotic Transport and Metabolism Genes NR1I2 and NR1I3 and Multiple Myeloma Risk: A Case-Control Study in the Context of IMMEnSE Consortium. Blood, 2011, 118, 5014-5014.	1.4	0
78	R-CHOP21 Vs R-CHOP14 in Diffuse Large B-Cell Lymphoma Patients: Results From a Multicentre Retrospective Study. Blood, 2011, 118, 1626-1626.	1.4	0
79	Molecular Remission After VTD or TAD As Induction for Multiple Myeloma: Results with Two Different Methods of Analysis.. Blood, 2012, 120, 2929-2929.	1.4	0
80	Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL). Blood, 2012, 120, 3653-3653.	1.4	0
81	CD69 Expression Predicts Favorable Outcome in Multiple Myeloma Patients Treated with VTD. Blood, 2015, 126, 1768-1768.	1.4	0
82	Role of Genetic Polymorphisms on Response to R-Chopregimen in Diffuse Large B-Cell Lymphoma Patients: An Interim Analysis of a Multicenter Prospective Pharmacogenetic Study. Blood, 2015, 126, 2483-2483.	1.4	0
83	Zinc Oral Supplementation Induces a Significant Rise of TRECs and T CD4+ Naïve and Prevents the Increase of Ttv Viral Load after Stem Cell Transplantation: The Zenith Study. Blood, 2016, 128, 1230-1230.	1.4	0
84	The hOCT1 and ABCB1 Polymorphisms Don't Condition the Efficacy and Toxicity of Nilotinib As First-Line Treatment: An Italian Multicentric Experience. Blood, 2016, 128, 3951-3951.	1.4	0
85	Safety and Efficacy of Rituximab and Cyclophosphamide in a Case of Resistant Acquired Hemophilia A in Course of Chronic Lymphocytic Leukemia. Cureus, 2019, 11, e5630.	0.5	0
86	A Comprehensive and Systematic Analysis of Minimal Residual Disease (MRD) Monitoring in Follicular Lymphoma: Results from the Fondazione Italiana Linfomi (FIL) FOLL12 Trial. Blood, 2021, 138, 41-41.	1.4	0